Earnings dates and session timing shown here are aggregated from third-party sources, are frequently estimated, and are subject to change or confirmation by the reporting company. Nothing on this site is financial advice.
20/20 Biolabs, Inc. (AIDX) is a pioneering biotechnology company dedicated to advancing genomic research and diagnostics through its cutting-edge laboratory services. Focused on improving the accuracy and efficiency of genetic testing for both clinical and research applications, the company is set to establish itself as a leader in the molecular diagnostics market. With a strategic emphasis on personalized medicine and a robust portfolio of state-of-the-art technologies, 20/20 Biolabs is well-positioned to meet the surging demand for genomic data and capitalize on emerging opportunities within the dynamic biotechnology landscape. Its innovative approach and strong market presence reflect a promising growth trajectory in an industry characterized by rapid advancements.
Quotes and fundamental data are delayed and provided for informational purposes only — nothing on this page is financial advice. Figures are as reported by the company and its data providers and may be revised. Estimates reflect analyst consensus at the time of each report.
$0.59
| Quarter | EPS | Revenue | Price move | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Est | Adj | Result | GAAP | Est | Actual | Surprise | 1D Pre | On-Day | 1D Post | |
Q ended Jun 30, 2026 Reported Aug 14, 2026 | $-0.12 | $-0.26 | Miss -116.7% | $-0.26 | $636.0K | $730.6K | +14.9% | 1D Pre+12.5% | On-Day+5.9% | 1D Post+0.2% |
Q ended Mar 31, 2026 Reported May 20, 2026 | $-0.10 | $-0.28 | Miss -180.0% | — | $779.0K | $353.4K | -54.6% | 1D Pre+1.5% | On-Day-3.7% | 1D Post-6.6% |
Q ended Dec 31, 2025 Reported Mar 31, 2026 | — | |||||||||
Dashed outlines show the analyst consensus estimate for periods where one was published. Hover or tap a bar for exact figures. Values as reported; not adjusted for splits after the report date.
| $-0.12 |
| — |
| — |
| — |
| $538.3K |
| — |
| 1D Pre-1.1% |
| On-Day+5.6% |
| 1D Post0.0% |
Q ended Sep 30, 2025 Report date n/a | — | — | — | — | — | $418.0K | — | 1D Pre— | On-Day— | 1D Post— |